Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
B0YJ81

UPID:
HACD1_HUMAN

ALTERNATIVE NAMES:
3-hydroxyacyl-CoA dehydratase 1; Cementum-attachment protein; Protein-tyrosine phosphatase-like member A

ALTERNATIVE UPACC:
B0YJ81; B0YJ80; Q6JIC5; Q96FW7; Q9HB93; Q9UHX2

BACKGROUND:
The protein Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 1, known alternatively as Cementum-attachment protein, is integral to the synthesis of very long-chain fatty acids (VLCFAs), serving as precursors for membrane lipids and lipid mediators. It also plays a role in dental health, particularly in cementum formation, essential for tooth attachment and integrity.

THERAPEUTIC SIGNIFICANCE:
Mutations affecting Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 1 are responsible for Congenital myopathy 11, characterized by significant muscle weakness and motor delays. Exploring the functions and mechanisms of this protein offers promising avenues for developing targeted treatments for such genetic disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.